Tesamorelin: research protocol, dosing & reconstitution
Also known as: Egrifta (brand)
Quick answer
What is Tesamorelin?
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone, notable as the only compound in its class with full FDA approval (as Egrifta, for reduction of visceral fat in specific patients). Researchers study it for body composition — particularly deep abdominal (visceral) fat.
What Tesamorelin is
Tesamorelin is a synthetic GHRH analog with a stabilizing modification that resists enzymatic breakdown, giving it stronger and longer GHRH-receptorReceptorA protein on or inside a cell that binds specific signaling molecules and triggers a response. Most peptides work by binding particular receptors.See glossary → activity than natural GHRH. It was developed clinically and approved as Egrifta for HIV-associated lipodystrophy.
Research vialsVialThe small sealed glass container peptides are supplied in, topped with a rubber septum that a syringe needle can pass through.See glossary → are commonly 2 mg, 5 mg, or 10 mg lyophilizedLyophilizedFreeze-dried. Peptides are shipped as a lyophilized powder ('puck') because the dry form is far more stable than a solution. It must be reconstituted before use in research.See glossary → powder. In Canada, pharmaceutical tesamorelin is a prescription drug; research-vendor versions are Research Use OnlyRUO (Research Use Only)A regulatory classification meaning a product is sold strictly for laboratory research and is not approved, labeled, or intended for human or veterinary use.See glossary →.
Mechanism of action
Tesamorelin binds pituitary GHRH receptors, increasing GHGH (growth hormone)A hormone produced by the pituitary gland involved in growth, metabolism, and tissue repair. Several research peptides are studied for their ability to stimulate GH release.See glossary → secretion and downstream IGF-1IGF-1 (insulin-like growth factor 1)A hormone produced mainly by the liver in response to growth hormone. IGF-1 levels are a common downstream marker in GH-axis research.See glossary →. Clinical trials in HIV-associated lipodystrophy reported significant reductions in visceral adipose tissue over 26 weeks of daily administration [1].
Its clinical pedigree gives it more published human data than most peptides on this site — a meaningful distinction for researchers comparing the GH-axis class.
What researchers study Tesamorelin for
- Visceral adipose tissue reduction (clinical data exists)
- Body-composition and metabolic research
- GH-axis and IGF-1 response studies
- Cognitive-aging research (early-stage studies)
What dose of Tesamorelin do researchers use?
Research literature commonly references doses of ~1–2 mg per day. This is not a recommendation — the table below summarizes protocols as they appear in published literature and trial designs.
| Context | Dose | Frequency | Duration |
|---|---|---|---|
| Clinical dosing reference (Egrifta) | 2 mg | Once daily | 26+ weeks in trials |
| Research literature reference | 1–2 mg | Once daily, often before bed | 8–12 week cycles referenced |
← Swipe to see the full table
Half-life and dosing timing
Half-life: Short (daily dosing). Route referenced in research: Subcutaneous, daily. Short half-lifeHalf-lifeHow long it takes for half of a compound to be eliminated from the body. Half-life determines how often researchers dose a compound in protocols.See glossary →; dosed daily. Protocols reference evening administration on an empty stomach, aligned with the nocturnal GH pulse.
Titration: start low, go slow
Literature-referenced protocols start at 1 mg daily for the first 1–2 weeks before moving to the 2 mg clinical-reference dose.
Skip the Tesamorelin math
Enter vial size, water volume, and target dose — the free calculator returns concentration, injection volume, and exact U-100 syringe units.
How is Tesamorelin reconstituted?
| Vial size | BAC water | Concentration | Worked example |
|---|---|---|---|
| 5 mg | 2.5 mL | 2 mg/mL | 1 mg = 0.5 mL = 50 units on a U-100 syringe |
| 10 mg | 2 mL | 5 mg/mL | 2 mg = 0.4 mL = 40 units on a U-100 syringe |
Add 2.5 mL of bacteriostatic waterBAC water (bacteriostatic water)Sterile water containing 0.9% benzyl alcohol, which suppresses bacterial growth. It is the standard diluent used to reconstitute lyophilized peptides for multi-dose research vials.See glossary → to a 5 mg vial: 5 ÷ 2.5 = 2 mg/mL. A 1 mg dose is 0.5 mL — 50 units on a U-100 syringeU-100 syringeAn insulin syringe calibrated so that 100 units equal 1 mL. The standard syringe referenced in peptide research; each unit equals 0.01 mL.See glossary →.
New to the process? Read the full step-by-step reconstitution guide.
How long does reconstituted Tesamorelin last?
Lyophilized: refrigerate. ReconstitutedReconstitutionThe process of mixing a freeze-dried (lyophilized) peptide powder with bacteriostatic water to create a solution of known concentration.See glossary →: refrigerate at 2–8°C and use within weeks; pharmaceutical labeling directs immediate use after reconstitution, so research references treat reconstituted stability conservatively.
What is Tesamorelin stacked with in research?
Referenced in GH-axis stacksPeptide stackTwo or more peptides used together in a research protocol because their mechanisms are complementary — for example, BPC-157 with TB-500.See glossary →, sometimes alongside secretagogues like Ipamorelin; also studied solo given its clinical data base.
Side effects observed in research
Reported in trials: injection-site reactions, joint pain (arthralgia), and fluid retention. GH-axis stimulation can affect glucose tolerance — monitored in the clinical program.
- Injection-site reaction
- Joint pain
- Fluid retention
Frequently asked questions
Is Tesamorelin approved in Canada?
Pharmaceutical tesamorelin (Egrifta) is a prescription drug approved for a specific indication. Research-vendor tesamorelin is sold strictly as Research Use Only.
What dose of Tesamorelin do researchers reference?
The clinical dose in trials was 2 mg once daily; research literature commonly references 1–2 mg daily. This describes published protocols, not a recommendation.
How is Tesamorelin different from CJC-1295?
Both are GHRH analogs, but tesamorelin carries full clinical-trial evidence and regulatory approval for visceral fat reduction, while CJC-1295 remains a research-stage compound.
Why is Tesamorelin studied for belly fat specifically?
Its pivotal trials measured visceral adipose tissue — deep abdominal fat around the organs — where it produced significant reductions versus placebo.
Related research peptides
CJC-1295
A growth-hormone-releasing hormone analog studied for stimulating GH release; often blended with Ipamorelin.
Growth Hormone SecretagogueIpamorelin
A selective ghrelin-receptor agonist / GH secretagogue studied for stimulating GH with minimal effect on cortisol or prolactin.
Healing & RecoveryBPC-157
A synthetic peptide fragment studied for tissue repair, tendon/ligament and gut healing in animal research.
Browse all Growth Hormone Secretagogue peptides or start with the beginner’s guide to research peptides.
References
- 1.Falutz J, et al. Effects of tesamorelin, a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat. N Engl J Med / AIDS trials program, 2007–2010. PubMed ↗